The monkeypox testing market is expected to evolve significantly as global health systems strengthen their preparedness against emerging infectious diseases. Continued outbreaks and the virus’s classification as a public health concern are pushing governments and healthcare providers to maintain robust diagnostic capacities. Advancements in molecular diagnostics—especially PCR assays, point-of-care tests, and rapid antigen kits—will enhance detection speed and accuracy. Rising investments in infectious disease surveillance, along with improved laboratory infrastructure in developing regions, will further support market expansion. Increased awareness, expanded screening programs, and integration of multiplex assays capable of detecting multiple orthopoxviruses are emerging trends. Pharmaceutical and biotech companies are also exploring advanced testing platforms, including at-home diagnostic kits and portable devices for field testing. As global travel resumes and zoonotic disease risks persist, the demand for reliable, scalable, and rapid monkeypox testing solutions is projected to remain strong, ensuring steady market growth in the coming years.